Ianalumab, Ibrutinib Combination Promising in Chronic Lymphocytic Leukemia
Researchers sought to determine whether combination therapy with ianalumab and ibrutinib would have efficacy in patients with CLL.
Researchers sought to determine whether combination therapy with ianalumab and ibrutinib would have efficacy in patients with CLL.
Researchers sought to better discriminate true MRD positivity for risk stratification in chronic lymphocytic leukemia and acute lymphoblastic leukemia in children.
Researchers sought to determine whether patients with CLL/SLL would be able to maintain fixed dosing schedule of venetoclax-based regimens in their treatments.
Researchers sought to determine the impact of exercise done at home by patients with chronic lymphocytic leukemia.
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.
Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
Researchers sought to determine whether uMRD could determine discontinuation of venetoclax or the addition of ibrutinib in patients with R/R CLL.
Researchers sought to determine whether adding anti-CD19 CAR-T cells to ibrutinib would improve remission rates in CLL.